The Different Mechanisms of Cancer Drug Resistance: A Brief Review

Overview

Journal Adv Pharm Bull

Date 2017 Oct 27

PMID 29071215

Citations 685

Authors

Behzad Mansoori

Ali Mohammadi

Sadaf Davudian

Solmaz Shirjang

Behzad Baradaran

Affiliations

Soon will be listed here.

Abstract

Anticancer drugs resistance is a complex process that arises from altering in the drug targets. Advances in the DNA microarray, proteomics technology and the development of targeted therapies provide the new strategies to overcome the drug resistance. Although a design of the new chemotherapy agents is growing quickly, effective chemotherapy agent has not been discovered against the advanced stage of cancer (such as invasion and metastasis). The cancer cell resistance against the anticancer agents can be due to many factors such as the individual's genetic differences, especially in tumoral somatic cells. Also, the cancer drug resistance is acquired, the drug resistance can be occurred by different mechanisms, including multi-drug resistance, cell death inhibiting (apoptosis suppression), altering in the drug metabolism, epigenetic and drug targets, enhancing DNA repair and gene amplification. In this review, we outlined the mechanisms of cancer drug resistance and in following, the treatment failures by common chemotherapy agents in the different type of cancers.

Citing Articles

Biological Activity of Peptide Fraction Derived from L. (Diptera: Stratiomyidae) Larvae Haemolymph on Gastric Cancer Cells.

Rinaldi R, Laurino S, Salvia R, Russi S, De Stefano F, Galasso R Int J Mol Sci. 2025; 26(5).

PMID: 40076512 PMC: 11899352. DOI: 10.3390/ijms26051885.

Improvement of carboplatin chemosensitivity in lung cancer cells by siRNA-mediated downregulation of DLGAP1-AS2 expression.

Alamdari S, Mohammadzadeh R, Amini M, Najafi S, Baradaran B, Bahojb Mahdavi S Sci Rep. 2025; 15(1):7971.

PMID: 40055367 PMC: 11889186. DOI: 10.1038/s41598-025-87649-6.

The epigenetic landscape of brain metastasis.

Powell A, Watson L, Luzietti L, Prekovic S, Young L, Vareslija D Oncogene. 2025; .

PMID: 40016470 DOI: 10.1038/s41388-025-03315-1.

Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance.

Ingham J, Ruan J, Coelho M BJC Rep. 2025; 3(1):11.

PMID: 40016372 PMC: 11868516. DOI: 10.1038/s44276-025-00129-2.

Bioconjugation of Podophyllotoxin and Nanosystems: Approaches for Boosting Its Biopharmaceutical and Antitumoral Profile.

Miranda-Vera C, Hernandez A, Garcia-Garcia P, Diez D, Garcia P, Castro M Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005983 PMC: 11859694. DOI: 10.3390/ph18020169.

References

Baguley B . Classical and Targeted Anticancer Drugs: An Appraisal of Mechanisms of Multidrug Resistance. Methods Mol Biol. 2016; 1395:19-37. DOI: 10.1007/978-1-4939-3347-1_2. View

Gatenby R, Gillies R, Brown J . Evolutionary dynamics of cancer prevention. Nat Rev Cancer. 2010; 10(8):526-7. PMC: 3744108. DOI: 10.1038/nrc2892. View

Pui C, Yang J, Hunger S, Pieters R, Schrappe M, Biondi A . Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015; 33(27):2938-48. PMC: 4567699. DOI: 10.1200/JCO.2014.59.1636. View

Kreitman R . Immunotoxins for targeted cancer therapy. AAPS J. 2006; 8(3):E532-51. PMC: 2761061. DOI: 10.1208/aapsj080363. View

Klopfleisch R, Kohn B, Gruber A . Mechanisms of tumour resistance against chemotherapeutic agents in veterinary oncology. Vet J. 2015; 207:63-72. DOI: 10.1016/j.tvjl.2015.06.015. View

de Vree J, Jacquemin E, Sturm E, Cresteil D, Bosma P, Aten J . Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A. 1998; 95(1):282-7. PMC: 18201. DOI: 10.1073/pnas.95.1.282. View

Garcia-Perez J, Lopez-Abente G, Gomez-Barroso D, Morales-Piga A, Pardo Romaguera E, Tamayo I . Childhood leukemia and residential proximity to industrial and urban sites. Environ Res. 2015; 140:542-53. DOI: 10.1016/j.envres.2015.05.014. View

Steelman L, Abrams S, Whelan J, Bertrand F, Ludwig D, Basecke J . Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia. 2008; 22(4):686-707. DOI: 10.1038/leu.2008.26. View

Luo J, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K . Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia. 2003; 17(1):1-8. DOI: 10.1038/sj.leu.2402725. View

10.

To K, Leung W, Ng S . Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp Cell Res. 2015; 338(2):222-31. DOI: 10.1016/j.yexcr.2015.09.011. View

11.

Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R . Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn. 2008; 11(1):4-11. PMC: 2607559. DOI: 10.2353/jmoldx.2009.080095. View

12.

Croop J, Raymond M, Haber D, DeVault A, Arceci R, Gros P . The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol. 1989; 9(3):1346-50. PMC: 362730. DOI: 10.1128/mcb.9.3.1346-1350.1989. View

13.

Mansoori B, Mohammadi A, Goldar S, Shanehbandi D, Mohammadnejad L, Baghbani E . Silencing of High Mobility Group Isoform I-C (HMGI-C) Enhances Paclitaxel Chemosensitivity in Breast Adenocarcinoma Cells (MDA-MB-468). Adv Pharm Bull. 2016; 6(2):171-7. PMC: 4961974. DOI: 10.15171/apb.2016.024. View

14.

Grandage V, Gale R, Linch D, Khwaja A . PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 2005; 19(4):586-94. DOI: 10.1038/sj.leu.2403653. View

15.

Settleman J . Cancer: Bet on drug resistance. Nature. 2016; 529(7586):289-90. DOI: 10.1038/nature16863. View

16.

Macconaill L, Garraway L . Clinical implications of the cancer genome. J Clin Oncol. 2010; 28(35):5219-28. PMC: 3020694. DOI: 10.1200/JCO.2009.27.4944. View

17.

Longley D, Johnston P . Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2):275-92. DOI: 10.1002/path.1706. View

18.

Li Z, Dalton W . Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev. 2006; 20(6):333-42. DOI: 10.1016/j.blre.2005.08.003. View

19.

Junttila M, de Sauvage F . Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501(7467):346-54. DOI: 10.1038/nature12626. View

20.

Beach L, Palmiter R . Amplification of the metallothionein-I gene in cadmium-resistant mouse cells. Proc Natl Acad Sci U S A. 1981; 78(4):2110-4. PMC: 319293. DOI: 10.1073/pnas.78.4.2110. View